This Medudy course is a video tutorial for physicians on the topic of
"MoonRISe-3: TAR-210 in high-risk non-muscle-invasive bladder cancer (NMIBC)".
High-risk NMIBC is one of the most clinically challenging entities in urology. Despite standard intravesical therapies such as BCG or chemotherapy, recurrence and progression rates remain high, so that in many cases radical cystectomy is ultimately the only treatment option.
The MoonRISe-3 study is the first to investigate an FGFR-targeted intravesical therapy approach in the high-risk NMIBC setting.
It uses TAR-210, an intravesical drug delivery system that continuously releases erdafitinib directly into the bladder over approximately 90 days.
The local, long-lasting exposure to the active ingredient is intended to achieve effective target structure blockade with low systemic exposure.
This course provides a concise and practical overview of the scientific rationale, study design, endpoints, and clinical relevance of the MoonRISe-3 study.
Note:
All "speakers" appearing in the Medudy videos are AI-based avatars used to improve the didactic quality of the videos. The individuals on whom the avatars are based have given their explicit consent for their use. All content is based on high-quality scientific sources and is created and reviewed by the Medudy team of physicians.
At the end of this training course, you will be familiar with:
– the clinical relevance of high-risk NMIBC and the high unmet need for treatment
– the biological role of FGFR2/3 alterations in NMIBC
– the mechanism of action and special features of the TAR-210 system
– the study design and endpoints of the MoonRISe-3 study
– the potential clinical significance of an FGFR-targeted intravesical therapy approach
